Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Reyataz Dosing For Renally-Impaired Patients Will Be Phase IV Study

Executive Summary

FDA is requesting that Bristol-Myers Squibb determine appropriate Reyataz dosing for patients with renal impairment in a Phase IV study

You may also be interested in...

Bristol Reyataz To Launch In July; Lipid Data Included In Labeling

Bristol-Myers Squibb will make Reyataz (atazanavir) available in July following the June 20 approval of the HIV treatment

Reyataz Lipid Effect Offers Benefit But Not In Lipodystrophy, Cmte. Says

The favorable lipid profile of Bristol-Myers Squibb's protease inhibitor Reyataz offers HIV patients a clinical benefit over other protease inhibitors, FDA's Antiviral Drugs Advisory Committee agreed May 14

Bristol Reyataz Gets Broad Label Vote Despite Concerns In Drug Experienced

Bristol-Myers Squibb's protease inhibitor Reyataz is on track for a June approval with a broad label recommendation following a positive advisory committee review May 13




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts